For example, the CDK9 inhibitor alvocidib showed encouraging clinical results for refractory AML through the MCL-1-dependent pathway, while several CDK 4/6 inhibitors are under development to downregulate the FLT3 and KMT2A genes in AML. This evidence concerns the gene KMT2A and acute myeloid leukemia.